ArticleScientific reports2021
Safety of PRRSV-2 MLV vaccines administrated via the intramuscular or intradermal route and evaluation of PRRSV transmission upon needle-free and needle delivery.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Comparing Pharmacokinetics of Meloxicam When Administered With a Needle-Free Injection Device Versus Needle-And-Syringe in Piglets.Journal of veterinary pharmacology and therapeutics · 2026Article
- A needle-free intradermal PEDV S protein vaccine elicits protective lactogenic immunity in piglets.Frontiers in cellular and infection microbiology · 2026Article
- Viral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions.Pathogens (Basel, Switzerland) · 2025Article
- Efficacy and Safety Evaluation of a Ready-to-Use Bivalent Porcine Circovirus Type 2 andVaccines · 2025Article
- Field Evaluation of a Ready-to-Use Porcine Circovirus Type 2 andVeterinary sciences · 2025Article
- The Evaluation of a Porcine Circovirus Type 2 (PCV2) Intradermal Vaccine Against a PCV2 Field Strain.Vaccines · 2025Article
- Field Investigation Evaluating the Efficacy of Porcine Reproductive and Respiratory Syndrome Virus Type 2 (PRRSV-2) Modified Live Vaccines in Nursery Pigs Exposed to Multiple Heterologous PRRSV Strains.Animals : an open access journal from MDPI · 2025Article
- Lineage 7 Porcine Reproductive and Respiratory Syndrome Vaccine Demonstrates Cross-Protection Against Lineage 1 and Lineage 3 Strains.Vaccines · 2025Article
- Review
- A Review of Swine Breeding Herd Biosecurity in the United States to Prevent Virus Entry Using Porcine Reproductive and Respiratory Syndrome Virus as a Model Pathogen.Animals : an open access journal from MDPI · 2024Review
- Review
- Effect of vaccination route (intradermal vs. intramuscular) against porcine reproductive and respiratory syndrome using a modified live vaccine on systemic and mucosal immune response and virus transmission in pigs.BMC veterinary research · 2024Article
- Needle-free intradermal vaccination, an opportunity to improve commercial pig welfare.Animal welfare (South Mimms, England) · 2024Article
- Article
- Codon Pair Deoptimization (CPD)-Attenuated PRRSV-1 Vaccination Exhibit Immunity to Virulent PRRSV Challenge in Pigs.Vaccines · 2023Article
- Intradermal needle-free injection prevents African Swine Fever transmission, while intramuscular needle injection does not.Scientific reports · 2023Article
- Review
- Time Farms Stay Naïve for Porcine Reproductive and Respiratory Syndrome.Animals : an open access journal from MDPI · 2023Article
- Evaluation of Intradermal PRRSV MLV Vaccination of Suckling Piglets on Health and Performance Parameters under Field Conditions.Animals : an open access journal from MDPI · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two distinct experiments (Exp) were conducted to evaluate the shedding and efficacy of 2 modified live porcine reproductive and respiratory syndrome virus (PRRSV) type 2 vaccines (MLV) when administered intramuscularly (IM) or intradermally (ID) (Exp A), and the potential of PRRSV transmission using a needle-free device (Exp B). One-hundred fifty-four, 3-week-old castrated-male, pigs were procured from a PRRSV-free herd. In Exp A, 112 pigs were randomly allocated into 4 groups of 21 pigs including IM/Ingelvac MLV (G1), IM/Prime Pac (G2), ID/Prime Pac (G3), and non-vaccination (G4). Twenty-eight remaining pigs were served as non-vaccination, age-matched sentinel pigs. G1 was IM vaccinated once with Ingelvac PRRS MLV (Ing) (Boehringer Ingelheim, Germany). G2 and G3 were IM and ID vaccinated once with a different MLV, Prime Pac PRRS (PP) (MSD Animal Health, The Netherlands), respectively. Following vaccination, an antibody response, IFN-γ-SC, and IL-10 secretion in supernatants of stimulated PBMC were monitored. Sera, tonsils, nasal swabs, bronchoalveolar lavage, urines, and feces were collected from 3 vaccinated pigs each week to 42 days post-vaccination (DPV) and assayed for the presence of PRRSV using virus isolation and qPCR. Age-matched sentinel pigs were used to evaluate the transmission of vaccine viruses and were introduced into vaccinated groups from 0 to 42 DPV. Seroconversion was monitored. In Exp B, 42 pigs were randomly allocated into 5 groups of 3 pigs each including IM/High (T1), ID/High (T2), IM/Low (T3), ID/Low (T4), and NoChal. Twenty-seven remaining pigs were left as non-challenge, age-matched sentinel pigs. The T1 and T2, and T3 and T4 groups were intranasally challenged at approximately 26 days of age with HP-PRRSV-2 at high (10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.